In its dossier, the drug manufacturer of vedolizumab presented no suitable data for the therapeutic indication Crohn’s disease or for ulcerative colitis, investigators conclude.
In its dossier, the drug manufacturer of vedolizumab presented no suitable data for the therapeutic indication Crohn’s disease or for ulcerative colitis, investigators conclude.